Compare ANNX & ARI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | ARI |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.1M | 884.4M |
| IPO Year | 2020 | 2009 |
| Metric | ANNX | ARI |
|---|---|---|
| Price | $3.81 | $6.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $15.43 | $8.00 |
| AVG Volume (30 Days) | ★ 3.4M | 3.2M |
| Earning Date | 11-09-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 15.77% |
| EPS Growth | N/A | ★ 183.51 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $271,589,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.57 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.54 | $6.11 |
| 52 Week High | $7.18 | $11.24 |
| Indicator | ANNX | ARI |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 44.14 |
| Support Level | $3.71 | $6.11 |
| Resistance Level | $4.37 | $6.47 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 47.12 | 60.56 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.